Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PhillUpBankson Jun 10, 2020 4:31pm

177 Views

Post# 31135538

RE:RE:RE:Management and IR are outright lying now.

I understand your viewpoint @ but why at this point. Scientists cherish their work especially when it is groundbreaking? He probably put more time into then his family. Scientists have ego and pride. Yes the money is good but I'm certain he is not broke. He is the founder. So again why tarnish your name with fraudulent activity that could be debunked by people on Stockhouse? Wouldn't more effort be put into covering your trail? This is the work of Bay st and Echelon and others to capitalize. This daily movement is not on the radar of men with a name to tarnish. Remember your name is your name and when that is compromised, good luck

Bullboard Posts

BlackBerry’s cost-cutting yields Q1 2024 savings